drugset
drugset / Trial / NCT05570539

Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation

NCT05570539 ↗

Phase 1 Completed 30 enrolled Bellus Health Inc. - a GSK company
Non-randomizedCrossoverOpen-labelTreatment

Summary

This is a Phase 1, Single-Centre, Open-Label, Two-Part, Sequential Cross-Over Study Designed to Assess the Pharmacokinetic Profile of BLU-5937 Following Administration of Extended Release Formulation Prototypes and an Immediate Release Reference Formulation in Healthy Male and Female Subjects

Timeline

Start
2022-10-07
Primary completion
2024-05-02
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Camlipixant Small molecule — Oral

Indications

No indication recorded.